Abstract
Introduction Lung cancer remain a leading cause of cancer-related death, largely due to its asymptomatic progression in early stages and the development of drug resistance. Non-small cell lung cancer (NSCLC) accounts for 80% of all lung cancer cases, with lung adenocarcinoma (LUAD) being the most prevalent subtype. Despite advancements in treatment, the 5-year survival rate for LUAD remains low. Therefore, exploring gene networks may reveal novel therapeutic targets and pave the way for improved
Method A comprehensive literature review was conducted across various databases containing multi- level genomic information. From this, a robust list of LUAD-related genes was curated. These genes were used to construct a weighted network based on KEGG pathway similarity. The network was subjected to clustering, hub gene detection, and gene ontology analysis. In parallel, a protein-protein interaction (PPI) network was constructed around these genes, which was further enriched with miRNA data to develop a gene-miRNA regulatory network.
Results Following our analysis, 48 genes were identified as crucial to LUAD. Many of these genes, along with their corresponding miRNAs, were found to be either upregulated or downregulated in LUAD tissues. The hub genes and miRNAs identified are believed to play key roles in the initiation and progression of LUAD. Our network analysis highlighted PIK3CA, BRAF, EGFR, ERBB2, FGFR3, MTOR, and TP53, along with KRAS, MET, and FGFR2, as potential biomarkers. Additionally, miR-17-5p and miR-27a-3p, which are notably implicated in LUAD, emerged as novel biomarker candidates.
Conclusion In conclusion, we employed a combination of bioinformatics techniques and database mining to derive a refined list of genes and miRNAs with high potential for further research in LUAD. We also identified core pathways that play a critical role in LUAD pathogenesis, providing a foundation for future studies aimed at developing more targeted therapeutic approaches.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data that were originally located at: dbGaP, TCGA, Disgenet, OpenTarget, UniProt, CancerHotspot, and ClViC databases.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at dbGaP, TCGA, Disgenet, OpenTarget, UniProt, CancerHotspot, and ClViC databases.
